PharmacoMicrobiomics: The Drug-Microbiome Portal

How Bugs Modulate Drugs?

Launched on 11/11/11; Current Release 1.5 (21 Mar 2021): Spring of Hope! (Release History)

Detailed View

Summary Gut microbes (phylum: Firmicutes) affect atezolizumab's activity.
atezolizumab (PubChem SID: 377483935)
Firmicutes (Tax ID: 1239)
affect activity
Immune checkpoint inhibitors (ICI) are recently being used to treat various types of cancers. ICI blocks checkpoint proteins allowing T cells to kill the cancer cells. In a study, a correlation between the microbiome profile of patients taking (nivolumab, pembrolizumab, or atezolizumab) as monotherapy with their overall survival is conducted. it was observed that patients with a high abundance of firmicutes( Ruminococcaceae and Agathobacter) in their gut microbiome show a favorable objective response rate of more than 6 months. in addition to patients with high Ruminococcaceae abundance show overall survival rates of more than 12 months.

Browse Drug-Microbiome Relationship